Gene expression profiling in stroke: relevance of blood–brain interaction. (February 2016)

• Record Type: Journal Article
• Authors: Asano, Shinichi; Chantler, Paul D; Barr, Taura L
• Is Part Of: Current opinion in pharmacology. Volume 26(2016)
• Page Start: 80
• Page End: 86
• Publication Date: 2016-02
• Subjects: Pharmacology -- Periodicals; Pharmaceutical Preparations -- Periodicals; Drug Therapy -- Periodicals; Biopharmaceutics -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Periodicals; 615.105
• DOI: 10.1016/j.coph.2015.10.004
• Languages: English
• ISSNs: 1471-4892

Abstract

Highlights: Expression prolife data suggest stroke involves a complex inflammatory response. Neutrophil and lymphocyte ratio may be a useful biomarker for stroke outcome. Arginase from neutrophil may play a role in stroke-associated immunosuppression. Abstract : Biomarker profiling is utilized to identify diagnostic and prognostic candidates for stroke. Clinical and preclinical biomarker data suggest altered circulating immune responses may illuminate the mechanisms of stroke recovery. However, the relationship between peripheral blood biomarker profile(s) and brain profiles following stroke remains elusive. Data show that neutrophil lymphocyte ratio (NLR) predicts stroke outcome. Neutrophils release Arginase 1 (ARG1) resulting in T lymphocyte suppression in peripheral blood. Interestingly, the cellular response to stroke may have implications for known biomarker profiles. Conversely, preclinical evidence suggests that upregulation of ARG1 in microglia is a marker of M2 macrophages and may influence neuroprotection. Comparing clinical and preclinical studies creates opportunities to explore the molecular mechanisms of blood and brain biomarker interactions in stroke.